Compounds > cholest-5-ene-3,4-diol
Page last updated: 2024-08-25

cholest-5-ene-3,4-diol and HIV Coinfection

cholest-5-ene-3,4-diol has been researched along with HIV Coinfection in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aklillu, E; Bakari, M; Bertilsson, L; Burhenne, J; Diczfalusy, U; Janabi, M; Minzi, O; Mugusi, F; Mugusi, S; Ngaimisi, E; Riedel, KD; Sasi, P; Suda, A; Ueda, N1
Bertilsson, L; Böttiger, Y; Diczfalusy, U; Flamholc, L; Gisslén, M; Josephson, F; Ormaasen, V; Sönnerborg, A1

Trials

1 trial(s) available for cholest-5-ene-3,4-diol and HIV Coinfection

ArticleYear
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.
    European journal of clinical pharmacology, 2008, Volume: 64, Issue:8

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Enzyme Induction; Enzyme Inhibitors; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxycholesterols; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Young Adult

2008

Other Studies

1 other study(ies) available for cholest-5-ene-3,4-diol and HIV Coinfection

ArticleYear
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:12

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Genotype; HIV Infections; Humans; Hydroxycholesterols; Male; Middle Aged; Rifampin; Tuberculosis

2014